Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
22.64
-0.15 (-0.66%)
Nov 20, 2024, 4:00 PM EST - Market open
Nurix Therapeutics Analyst Ratings
Total Analysts
15
Consensus Rating
Strong Buy
Price Target
$29.33
Upside
+29.55%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +28.09% | Nov 6, 2024 |
| UBS | UBS | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +54.59% | Oct 24, 2024 |
| Needham | Needham | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +28.09% | Oct 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $30 | Strong Buy | Maintains | $26 → $30 | +32.51% | Oct 21, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $27 → $26 | Buy | Maintains | $27 → $26 | +14.84% | Oct 14, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $31 | Buy | Reiterates | $31 | +36.93% | Oct 14, 2024 |
| Needham | Needham | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +28.09% | Oct 14, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $41 | Strong Buy | Initiates | $41 | +81.10% | Oct 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $27 → $30 | Buy | Maintains | $27 → $30 | +32.51% | Sep 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $27 | Buy | Maintains | $25 → $27 | +19.26% | Aug 14, 2024 |
| Truist Securities | Truist Securities | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +59.01% | Jul 31, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $31 → $34 | Buy | Maintains | $31 → $34 | +50.18% | Jul 15, 2024 |
| Barclays | Barclays | Buy Maintains $20 → $31 | Buy | Maintains | $20 → $31 | +36.93% | Jul 15, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +19.26% | Jul 12, 2024 |
| Needham | Needham | Strong Buy Maintains $31 → $29 | Strong Buy | Maintains | $31 → $29 | +28.09% | Jul 12, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $23 → $26 | Buy | Maintains | $23 → $26 | +14.84% | Jun 27, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.